HBOT Conversations:
Robert Beckman & NBIRR Study
Robert Beckman, Ph.D., Founder of the TreatNow Coalition in Arlington, Virginia, discusses the National Brain Injury Rescue Rehabilitation study focused on the use of Hyperbaric Oxygen Therapy for brain injuries. Beckman has a passion for data and helping veterans, which is what ultimately got him first involved in Hyperbaric Oxygen Therapy back in 2008. He was one of many, participating with an elite group of doctors and HBOT experts, who organized and oversaw the results of NBIRR, a multi-center HBOT trial for mild traumatic brain injury with post-concussive symptoms.
The TreatNow Coalition’s Mission is to Stop service member suicides by identifying and treating veterans and others suffering from brain wounds, TBI, PTSD, and Concussion.
Watch the Podcast
HBOT News podcast host, Edward di Girolamo, talks with guest, Robert Beckman, founder of Treatnow.org, who was instrumental in the compilation and release of The National Brain Injury Rescue and Rehabilitation Study – a multicenter observational study of hyperbaric oxygen for mild traumatic brain injury with post-concussive symptoms.
It took over a decade for that study to be completed and published. Once it was, it not only opened a door for veterans and others who were looking for a way to heal from head trauma, the NBIRR study ignited other studies to start, focusing solely on the safety & efficacy of Hyperbaric Oxygen Therapy for brain injuries.
Beckman discusses some of the challenges he has witnessed over the years, including the Army declaring that HBOT does not work. After combing through the data, Beckman states that their analysis is rooted in a “lie” about the sham they used in their study; everyone got better. This starts an in-depth conversation between di Girolamo and Beckman about the frustration of the government so easily dismissing HBOT, inflammation linked to PTSD, the stigma of PTSD being a personal and not a physical problem, the disappointment that most veterans don’t even know HBOT exists, and why more is not being done to heal our veterans from these invisible injuries of war.
Beckman proudly states that what started as nine clinics to treat veterans under the NBIRR study, has grown to about 135 clinics across the country that specialize in treating veterans with HBOT for free or reduced rates. Additionally, there are now a combined 12,500-plus success stories from these 135 clinics of individuals with TBI, PTSD, and mTBI who have completed 40 treatments/dives.
Beckman gives surgical statistics relating to HBOT and explains that by pre-oxygenating and post-oxygenating via hyperbaric chambers, patients can benefit from a 30-40% faster healing rate. He points out that countless professional athletes are now using hyperbaric oxygen therapy for faster recuperation to treat pain, injuries, and inflammation; and hyperbarics is being used all over the world right now for successfully treating COVID long-haulers. He states that COVID long-haulers are hypoxic suffering patients, and data exists that military personnel who have experienced the blow of an IUD are suffering in much of the same manner – it’s that lack of oxygen to the brain and all parts of the suffering body that HBOT helps.
di Girolamo asks the question so many of us are curious about, “If HBOT obviously works, why isn’t the military admitting to this? Why aren’t we using it more?” Beckman suggests we read this particular blog on his website that sheds much light on the subject, The Obvious Question: If HBOT works, why aren’t we using it?
Beckman reminds di Girolamo – and all of us – that this is a marathon. Yes, they’ve made great strides over the past two decades in education and research for hyperbaric oxygen therapy, but they still have a way to go. He continues to be optimistic that one day we’ll all witness our shared goal of eliminating the suicide epidemic by utilizing HBOT to thoroughly heal brain injuries.
Guest
Robert L. Beckman, Ph.D.
Dr. Beckman has been building knowledge management systems most of his professional career, primarily in the Intelligence Community and DOD. He is currently helping to run the Clinical Trial researching TBI and PTSD in brain-injured wounded warriors. He is responsible for sustaining the national network of hyperbaric clinics as well as improving the technology platform for data collection and analysis. He is a former USAF KC-135 pilot and a Vietnam Veteran.
TreatNow.org
(571) 549-4258
beckmanr88@gmail.com
Contact TreatNow.org
https://treatnow.org/
Subscribe Now, It’s Free !
Recent HBOT News
Clinical Trial – Dose and Response of Intrathecal Hydromorphone in Patients Undergoing Cesarean Section at Virginia Commonwealth University Health System
In the United States the incidence of cesarean deliveries have increased over the last
several decades and is currently approximately 30% nationwide. The anesthesia and analgesia
for elective c-sections vary between institutions.
Parturients present a unique challenge for the anesthesiologist as the mother has to care not
only for herself, but also for the newborn postpartum. While intrathecal opioids provide
adequate pain relief, they do so at the cost of bothersome side effects for patients, such as
pruritus and nausea/vomiting.
Intrathecal hydromorphone has started to be explored as a new option for intrathecal
analgesia. A study done by Beatty et al. showed in a retrospective review that 40 mcg of
intrathecal dilaudid was safe and effective as compared to intrathecal morphine for analgesia
after cesarean delivery. Additionally they showed no difference in side effect profiles of
the two medications. Mhyre et al. investigated the use of 100 mcg of intrathecal dilaudid
with hyperbaric bupivacaine in varying dosages for labor analgesia. The results were
inconclusive, but the dosage of hydromorphone was reported to be without adverse effects.
Virginia Commonwealth University Health Systems has successfully instituted the use of
intrathecal morphine with superior analgesia but with undesired side effects, most notably
pruritus. Recent drug shortages of duramorph have prompted investigators to seek alternative
options for post cesarean section analgesia. The investigators are interested in determining
the dose, efficacy, and side effect profile of intrathecal hydromorphone. Although our
institution has never utilized intrathecal hydromorphone for our patient population, it has
been studied at various other institutions where it has been found to be safe and efficacious
with an acceptable side effect profile.
Repeat spinal anesthesia in cesarean section: A comparison between 10 mg and 12 mg doses of intrathecal hyperbaric (0.05%) bupivacaine repeated after failed spinal anesthesia: A prospective, parallel group study.
Abstract: Spinal anesthesia for cesarean section is not a 100% successful technique. At times, despite straightforward insertion and drug administration, intrathecal anesthesia for cesarean section fails to obtain any sensory or motor block. Very few studies and...
Endocan reduces the malign grade of gastric cancer cells by regulating associated protein expression.
Abstract: Endocan, which has been identified to be low expressed in gastric cancer, was found to be positively related to the differentiation level of gastric cancer in vivo and in vitro. In the present study, we aimed to investigate the role of endocan in gastric...